RxDoctor Payments Data

Richard Cheng, MD

Cardiovascular Disease · Los Angeles, CANPI 1437426699

Payments from drug & device makers

$427,757in general payments, 2019–2025

Across 114 payments — averaging $3752.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procyrion, Inc.$255K
  • Edwards Lifesciences$166K
  • Abbott$3K
  • Ancora Heart, Inc.$1K
  • Siemens Medical Solutions USA, Inc.$1K
  • Heartflow, Inc.$283
  • plus $640 from 8 others

What the payments were for

  • Consulting fees$3,97534%
  • Travel & lodging$2,12418%
  • Food & beverage$5,69048%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$427,757 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$159,038
Medicare patients
270
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$64,762
EntrestoSacubitril/Valsartan29$42,571
EliquisApixaban30$34,941
Praluent PenAlirocumab11$4,981
Tacrolimus15$1,891
Bumetanide29$1,781
Fluconazole11$469
Metoprolol Succinate33$439
Gabapentin19$428
Bisoprolol Fumarate17$364
Spironolactone64$357
Warfarin Sodium18$315
Isosorbide Mononitrate ErIsosorbide Mononitrate13$286
ClopidogrelClopidogrel Bisulfate22$231
Losartan Potassium23$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$64,76249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →